Introduction
============

Cytological investigation of the cervix has proven to be a valuable tool in the early detection of cervical cancer. However, one of the problems limiting the value of cytological screening is the occurrence of false-negative test results \[[@b1]\]. Therefore, setting up quality control (QC)-systems to reduce this false-negative rate is a major issue in laboratories performing cervical cytology screening. QC of cervical cytology remains a matter of debate since there are wide differences in practice between laboratories and there has been little attempt to standardize the technique \[[@b2]\]. Many published studies also use a cytological or ill-defined end-point. Clinical testing procedures designed to identify pre-invasive, and invasive neoplastic disease should be evaluated for the detection of clinically relevant disease (high-grade lesions) and should not merely be judged on the increase of detection of low-level abnormalities \[[@b3]\].

Rescreening slides interpreted as negative is a QC method specially designed to address this sensitivity problem inherent to the interpretation of cervical cytology \[[@b4]\].

Full rescreening of a 10% random fraction of smears reported as being within normal limits is a mandatory QC procedure in the United States \[[@b5], [@b6]\]. This QC method is criticized for its inefficiency and lack of statistical power \[[@b7], [@b8]\]. In the United Kingdom, rapid or partial reviewing (RR) of all smears initially interpreted as being non-abnormal has been introduced as an alternative and more useful QC standard \[[@b9]--[@b13]\]. Meta-analysis showed that RR of all negative slides of rapid prescreening (RPS) of the full workload, resulted in the detection of more additional abnormalities in comparison with full rescreening of only 10% of the negative workload \[[@b14]\].

It could be hypothesized that limiting the rescreening to high-risk human papillomavirus (HR HPV) positive slides (HR HPV-targeted reviewing) the efficiency would increase. In this way, the size of the rescreening target group could be reduced, limiting the additional workload.

BD FocalPoint™ (previously AutoPap) is a computerized scanning system for the primary screening of cervical smears (BD Diagnostics-Tripath; Burlington, NC, USA). The system classifies smears into three different categories: (1) no further review (NFR), these smears can be stored with confidence as 'No Intra-epithelial Lesion or Malignancy' without being evaluated by a cytologist; (2) guided review or guided screening (GS), and (3) process review (PR), smears needing to be reviewed manually because of technical problems. The system provides a fixed proportion of 25% of NFR smears, as recommended by the manufacturer and approved by the Food and Drug Administration (FDA).

BD FocalPoint™ ranking system, classifying approximately 75% non-NFR slides in five quintiles, has been shown to correlate with the probability that a significant epithelial abnormality will be found \[[@b15]\]. Previously reported clinical trials have shown superior performance for the detection of all abnormal cases when compared with manual screening \[[@b16]\]. BD FocalPoint™ can be described as a system of RPS, defined as an initial, rapid microscopic inspection of a slide before a full routine evaluation \[[@b17]\]. The essential difference between RPS and GS is that in the latter all slides are submitted to a thorough uniform scanning by BD FocalPoint™ while in RPS there is only a quick scanning by a cytotechnologist.

In the current prospective study, three different QC methods for the detection of relevant disease (histologically proven CIN2+) in negative cytology are compared (full rescreening, HR HPV-targeted reviewing and detection of HR HPV). To test the relative sensitivity of the three different QC methods in a highly negative population, the number of CIN2+ cases identified by each method after 36 months of follow-up was investigated. The negative cytology samples were derived from three sources: NFR, GS and manual screening (MS).

From the results of the analysis of the tested schemes new recommendations for QC are formulated.

All investigations were conducted in the laboratory of clinical pathology, a private laboratory member of the AML-Riatol group. Riatol has used liquid-based cytology since 1998, analyzing approximately 100,000 slides per year.

Material and methods
====================

Cervical sample processing and cytological procedure
----------------------------------------------------

Cervical cells were collected using the Cervex-Brush® (Rovers, Oss, The Netherlands). After collection, brush heads were transferred directly into alcohol-based preservative (BD SurePath™, BD Diagnostics-TriPath), and the vials were transported to the laboratory. Thin layer slide preparations were made with the fully robotic AutoCyte® PREP System (AutoCyte®, BD Diagnostics-TriPath) \[[@b18]\], and were prepared as described elsewhere \[[@b19]\].

The cytological results were classified according to the Bethesda system 2001 \[[@b20]\], using the classes negative for intraepithelial lesions (NEG), atypical squamous cells of undetermined significance (ASC-US), low-grade squamous intraepithelial lesions (L-SIL), ASC-US cannot exclude high-grade (ASC-H) and high-grade SIL (H-SIL).

Screening procedure and patients
--------------------------------

Samples were collected during routine gynaecological health checks from women resident in the Flemish region (Belgium) by general practitioners or gynaecologists. Between April 2003 and August 2003, the first 230 slides of the daily load were loaded onto BD FocalPoint™, and the rest of the slides were screened manually. Smears that could not be interpreted by BD FocalPoint™ for technical reasons (PR) were also screened manually (MS). During that period full manual rescreening (FRE) was performed on an approximately 5% random sample of the smears labelled by BD FocalPoint™ as 'NFR' and of the samples screened manually and interpreted as being negative (Fig. [1](#fig01){ref-type="fig"}). All rescreen-positive cases (ASC-US+) were checked by a cytopathologist and a pathologist. The rescreening results were blinded from the HPV results. From January 2004 until December 2004 one random slide per screener per day (1/80--90) was taken from normal cytology after prescreening and GS with BD FocalPoint™ (GS). All slides from the GS group were also rescreened. All samples from the three groups (NFR, MS and GS) were tested for the presence of high-risk (HR) HPV types, using the liquid-based cytology leftover, after the preparation of the SurePath smear. All slides positive for one or more oncogenic HPV types were rescreened by a cytotechnician and reinterpreted by the pathologist (aware of HPV type but blinded for viral load and for the study population (NFR, GS, MS)). The algorithm of the study design is given in Figure [1](#fig01){ref-type="fig"}. Slides positive for unidentified (HPVX) HPV types were not rescreened.

![Algorithm study design.](jcmm0013-4051-f1){#fig01}

Patient identifiers were coded to preserve confidentiality.

BD FocalPoint™-guided screening
-------------------------------

All slides were scanned by BD FocalPoint™ system and categorized as qualified or PR. PR slides were screened manually. Qualified slides were categorized into five quintiles (75%, review slides) or as NFR, 25%, based on slide score. Slides in quintile 1 (Q1) have the highest probability of containing cytological abnormalities and Q5 the category the lowest probability. Slides classified as NFR immediately were designated as 'negative for intraepithelial lesions' with no manual review performed (except for slides with history, which were always manually reviewed, slides with a clinical history were excluded from the study population). 'Review' slides were screened using SlideWizards™ (BD-Diagnostics-Tripath) with GS by cytotechnologists with knowledge of the relative score ranking of each slide, given as quintiles within the 'Review' category, using the 15 PapMaps. After looking at the 15 PapMaps, each cytotechnician rapidly reviewed the entire slide (15 sec). BD FocalPoint™ and SlideWizards™ were used according to the manufacturer\'s instruction. In addition, as a positive control, a known slide previously diagnosed as H-SIL (CIN 3 biopsy confirmed and positive for HPV 16) was loaded in between the routine samples each day onto BD FocalPoint™. This control slide was always classified in the first quintile of the review category.

Isolation of DNA from cervical cells
------------------------------------

DNA isolation from liquid-based cytology was performed as previously described \[[@b21]--[@b23]\]. Briefly, half of the 800 μl liquid-based preparations leftover was used for DNA extraction by Proteinase K. This was to ensure that there is still enough material left to prepare an extra slide, or do a second DNA extraction. The DNA extracts were stored at −20°C until PCR was performed.

PCR analysis of HPV DNA
-----------------------

Each sample was subjected to a quantitative real-time PCR amplification for the detection of β-Globin. This was done to confirm that the DNA quality was still suitable for PCR analysis, and to be able to calculate the viral load. All samples were tested with the MY 9/11 consensus PCR \[[@b21], [@b23]\], and with type-specific quantitative real-time PCR for oncogenic HPV types. The copy number and viral load of HPV type 16 E7, 18 E7, 31 E6, 33 L1, 33 E6, 35 E4, 39 E7, 45 E7, 51 E6, 52 L1, 52 E7, 53 E6, 56 E7, 58 L1, 58 E6, 59 E7, 66 E6 and 68 E7 was determined using a *Taq*Man-based real-time qPCR analysis as previously described \[[@b22], [@b23]\].

The amount of β-globin DNA (in nanograms) present in each sample was divided by the weight of 1 genome equivalent (i.e. 6.6 pg/cell) and a factor of 2 (since there are two copies of β-globin DNA/cell) to obtain the number of genome equivalents in the sample. Viral loads in each specimen were expressed as the number of HPV copies/cell.

CIN 2+ cases and follow-up period
---------------------------------

For all samples included in the QC series, a 36-month follow-up period was used. Our computer system was searched to identify cases with biopsy-proven CIN 2+. As golden standard a CIN2+ histological outcome was considered as a positive follow-up result. Cytological follow-up was only included when minimum two consecutive negative smears were available, which was considered as absence of CIN 2+. For 1215 out of 1717 samples follow-up was available (70.8%). An overview of the number of follow-up cytology, of cytology with HPV status and of biopsies taken in each of the QC series is given in Table [1](#tbl1){ref-type="table"}.

###### 

Follow-up of negative cytology from: prescreening with BD FocalPoint™ (NFR), review of the prescreened slides by guided screening with SlideWizard (GS), and manual screening (MS)

                Follow-up by                                               
  ------------- -------------- ----- ------ ----- ------ ----- ----- ----- ------
  Study group   *n*            n     \%     *n*   \%     *n*   \%    *n*   \%
  NFR           506            332   65.6   21    4.2    33    6.5   150   29.6
  MS            498            327   65.7   26    5.2    21    4.2   143   28.7
  GS            713            79    11.1   425   59.6   51    7.2   209   29.3
  Total         1717           738   43.0   472   27.5   104   6.1   502   29.2

Statistical analysis
--------------------

Comparisons of means were studied by analysis of variance (ANOVA). The Chi-square statistics for trend was used to verify the existence of a trend across ordered groups, such as increase in HPV positivity according to the degree of cytological abnormality. Statistical tests were considered significant at *P* \< 0.05.

Results
=======

From April until August 2003, 35,460 liquid-based preparations were prepared for routine cervical screening (Fig. [1](#fig01){ref-type="fig"}). During that 5-month period, the first 230 slides received that day were loaded onto BD FocalPoint™ for prescreening (*n*= 31,643). Each day the rest of the available slides were screened manually (*n*= 3817). Also slides that failed processing by BD FocalPoint™ were screened manually (*n*= 4898). During that 5-month period 26,745 slides were qualified by BD FocalPoint™, 6591 slides were classified as NFR (24.6%) and 20,154 slides were classified as Review (75.4%). From the qualified slides, selected by BD FocalPoint™ as NFR (*n*= 6591) 506 slides were randomly selected for manual rescreening and HPV typing. From the manually screened slides with normal cytology (*n*= 8124), 498 slides were randomly selected for manual rescreening and HPV typing (MS).

In 2004, BD FocalPoint™ processed 86,154 slides, 5747 slides were excluded because of failed processing (1233 rerun and 4514 PR). From the remaining 80,407 qualified slides, 18,375 slides were classified as NFR (22.85%) and 62,032 slides were classified as Review (77.15%). From the review slides, 713 slides (1.15%), which were cytologically negative after GS, were randomly included for QC with oncogenic HPV detection and rescreening (GS).

A thorough search of our laboratory result database for the 1717 cytological normal slides included in the study, revealed 17 CIN 2+ cases (Table [2](#tbl2){ref-type="table"}).

###### 

Overview of biopsy confirmed CIN 2+ cases

  Case \#   Study group   FRE      ONC+RE   HPV                                            Viral load   Histology
  --------- ------------- -------- -------- ---------------------------------------------- ------------ -----------
  A         GS            NEG      NEG      16                                             0.0429       CIN 3
  B         GS            NEG      NEG      16                                             10.0861      CIN 2
  C         GS            L-SIL    ASC-US   16                                             8.3974       CIN 3
  D         GS            ASC-US   L-SIL    16[\*](#tf2-2){ref-type="table-fn"},39         1186.5076    CIN 3
  E         GS            ASC-US   H-SIL    18[\*](#tf2-2){ref-type="table-fn"},31,33,58   71.6029      CIN 3
  F         GS            NEG      NEG      39                                             0.7781       VIN 3
  G         MS            H-SIL    ASC-US   31                                             0.5285       CIN 3
  H         MS            NEG      NEG      31[\*](#tf2-2){ref-type="table-fn"},35         0.0144       CIN 2
  I         MS            NEG      NEG      18                                             6.6268       CIN 3
  J         NFR           NEG      NEG      16[\*](#tf2-2){ref-type="table-fn"},58         50.5446      CIN 3
  K         NFR           NEG      ASC-H    16                                             26.6882      CIN 3
  L         GS            NEG      NEG      16                                             0.3359       CIN 3
  M         GS            NEG      L-SIL    16                                             13.6599      CIN 3
  N         GS            NEG      ASC-R    16[\*](#tf2-2){ref-type="table-fn"},33         18.7129      CIN 3
  O         GS            NEG      ASC-H    16                                             2.9539       CIN 2
  P         GS            NEG      NEG      16                                             0.1970       CIN 2
  Q         NFR           NEG      NEG      16,33[\*](#tf2-2){ref-type="table-fn"},53      186.7860     CIN 3

FRE = full manual rescreening without knowledge of quintile ranking or HPV status, ONC+RE = HR HPV targeted rescreening, e.g. with knowledge of oncogenic HPV type but without knowledge of the viral load

= only the viral load for the HPV type with the highest load is given. Viral load is expressed as HPV copies/cell.

Full rescreening of NFR, GS and MS
----------------------------------

After full manual rescreening (FRE) of NFR, GS and MS, in total 19 slides were diagnosed as abnormal, 3 LSIL in the NFR group (0.59%), 11 in the GS group (1.54%) 7 ASC-US and 4 L-SIL, and 5 in the MS group (1.00%), 1 HSIL, 2 LSIL and 2 ASC-US. There was no significant difference between the numbers of abnormal slides detected in each group. The results from the rescreening, HPV typing and rescreening of the slides positive for oncogenic HPV types in the NFR, GS and MS groups is given in Table [3](#tbl3){ref-type="table"}.

###### 

Comparison of negative cytology from: prescreening with BD FocalPoint™ (NFR), review of the prescreened slides by guided screening with SlideWizard (GS), and manual screening (MS)

                   NFR     GS      MS                                                                                              
  ---------------- ------- ------- ---------- ----------------- -------------- ----------------------------- ---------- ---------- -------------
  16,(18)          4               ASC-H^K^   25^A,B,L,P^ (2)   2L-SIL^C^      6ASC^C^,2L-SIL^M^, ASC-H^O^   7          L-SIL      2ASC-H,ASC
  16,31,(35)                                  2(2)              ASC            ASC                                                 
  16,33,(39)       1                          1(1)                             ASC                                                 
  16,33,53         1 ^Q^                                                                                                           
  16,(35),39       1                          3                 ASC^D^         L-SIL^D^                                            
  16,51                                       1                                                                                    
  16,52                                       1                                                                                    
  16,58            1 ^J^                                                                                                           
  18,31                                       1                                ASC                                                 
  18,(31,33,58)    6               ASC        8(1)              ASC,(ASC^E^)   L-SIL,(H-SIL^E^)              17^I^                 6ASC
  18,39,(52)                                  1^N^ (1)          ASC            ASC-H                                               
  18,51,52                                    1                 L-SIL          H-SIL                                               
  18,56                                       1                                ASC                                                 
  18,58                                       1                                                                                    
  31                                          13                                                             4          H-SIL^G^   2ASC^G^
  31,33,(39)                                  1(1)                                                           \(1\)                 ASC
  31,33,52                                    1                                                                                    
  31,35,39,58                                 1                                ASC                                                 
  31,35,(53)       3               ASC,AGUS                                                                  1^H^ (1)              
  31,35,56         1                                                                                                               
  31,39                                       1                                ASC                           1                     ASC
  31,52                                       1                                                                                    
  33               1                          5                                ASC                           1                     
  33,52                                       1                                ASC                                                 
  35,(39)                                     4(1)                             ASC                           1                     
  35,52                                       1                                                                                    
  35,53                                       1                                                                                    
  35,58                                       1                                                                                    
  39,(52)          1       L-SIL   ASC        10^F^             ASC            L-SIL,ASC                     2(1)                  ASC,(ASC)
  45                                          1                                                                                    
  51,(53)          \(1\)                      9(2)                             ASC                           2                     
  51,66                                       1                                                                                    
  52,(53)          3                          7                                2ASC                          2(1)                  L-SIL,(ASC)
  52,58                                       2                                                                                    
  53               2                          8                                2ASC                          1                     
  56,(66)          1                          8(1)                             ASC                           1                     
  58               1                          7                                ASC,ASC-H                     2                     ASC
  66               3       L-SIL   L-SIL      8                                                              4          L-SIL      L-SIL
  68                                          3                                                                                    
  X+               58      L-SIL   ND         258               ASC,L-SIL      ND                            50                    
  Neg              417                        302                                                            398        2ASC       ND
  Total            506     506     31         713               713            153                           498        498        50
  Abnormal/Onc+    31      3       6          153               11             33                            50         5          19
  \%               6,1     0,6     19,4       21,5              1,5            21,6                          10,0       1,0        38,0
  Detected CIN2+   3       0       1          11                3              5                             3          1          1
  \%               100     0       33,3       100               27,3           45,5                          100        33,3       33,3

HPV = number of cases positive after HPV typing, FRE = full manual rescreening without knowledge of quintile ranking or HPV status, ONC+RE = HR HPV targeted rescreening, ND = not done, ^A-Q^ CIN 2+ biopsy confirmed cases.

In this study, a false positive rescreen result was defined as a case classified as abnormal (\>ASC-US) at rescreening by the cytotechnologist, but HPV negative and confirmed by the pathologist as being negative for intraepithelial neoplasia. The false positive rate of full rescreening was 0% in NFR and GS and 40% in MS.

Yield of additional abnormal slides picked up by high-risk (HR) HPV-targeted rescreening
----------------------------------------------------------------------------------------

The HR HPV rate was 6.1%, 10.0% and 21.6% in, respectively, the NFR, MS and GS group.

By targeted HR HPV rescreening four additional cytologically abnormal cases were identified in the NFR group (200%), 24 in the GS group (267%) and 16 in the MS group (533%; for details see Table [3](#tbl3){ref-type="table"}).

Comparison of the relative sensitivity of FRE versus HR HPV-targeted rescreening
--------------------------------------------------------------------------------

The relative sensitivity is calculated as the detection rate of confirmed ASC-US+ CIN2+ cases picked up by full rescreening over that picked up by HR HPV-targeted rescreening. Since none of the CIN2+ cases were picked up by full rescreening in the NFR group, no relative sensitivity could be calculated for the NFR group. The relative sensitivity was 50% in the GS group and 100% in the MS group. Overall relative sensitivity of general rescreening *versus* HR HPV-targeted screening was 50%.

Specificity and PPV of full rescreening, HR HPV-targeted reviewing and HR HPV detection
---------------------------------------------------------------------------------------

The specificity to detect CIN2+ by full rescreening was 99.1%, 76.5% by HR HPV-targeted reviewing and 87.2% by detection of HR HPV. PPV for finding an underlying CIN2+ lesion was 21%, 12% and 7% for, respectively, full rescreening, HR HPV-targeted reviewing and HR HPV detection; an overview for each individual QC group is given in Table [4](#tbl4){ref-type="table"}.

###### 

Overview of relative sensitivity, specificity and PPV for detection of CIN 2+ in the different QC groups for each of the QC screening methods

  QC Method          QC group   Relative sensitivity   Specificity   PPV
  ------------------ ---------- ---------------------- ------------- ------
  Full rescreening   all        23.5                   99.1          21.1
  NFR                0          93.8                   0             
  MS                 33.3       90.1                   2.0           
  GS                 27.3       78.6                   2.0           
  HR HPV             all        41.2                   76.5          12.1
  targeted           NFR        33.3                   94.0          3.2
  rescreening        MS         33.3                   90.1          2.0
  GS                 54.6       79.1                   3.9           
  HR HPV             all        100                    87.2          7.3
  detection          NFR        100                    94.4          9.7
  MS                 100        90.5                   6.0           
  GS                 100        79.8                   7.2           

PPV = positive predictive value.

Efficiency of full rescreening *versus* HR HPV-targeted reviewing and detection of HR HPV
-----------------------------------------------------------------------------------------

Finally, general full rescreening of 1717 slides allowed detection of only four histological confirmed CIN 2+ cases (0.23%), whereas HR HPV-targeted rescreening of only 234 HR HPV positive slides yielded detection of eight CIN2+ cases (3.42%). This means that HR HPV-targeted rescreening is 15 times more sensitive than full reviewing as QC method. All CIN 2+ cases detected in follow-up were positive for one or more oncogenic HPV types. Detection of HR HPV (7.3%) without screening was 32 times more sensitive than full reviewing.

Rank *versus* viral load
------------------------

For slides in the GS group, BD FocalPoint™ assigned each slide a group ranking, ranging from 1 to 5, where a rank of 1 indicates the group most likely to contain abnormalities. The group ranking in function of HPV positivity and cytology is given in Table [5](#tbl5){ref-type="table"}. The difference in viral load between ASC-US+ and Neg cases is highest in the 1^st^ and 2^nd^ quintile, and non-existing in 3^rd^--5^th^ quintile (ANOVA F-ratio = 2.298; *P*= 0.019).

###### 

Quintile ranking in function of HPV positivity and cytology after HR targeted rescreening of samples from the GS group

                  Quintile                                    Total
  -------- ------ ---------- -------- ------- --------- ----- -------
  NEG      \-     52         53       61      73        63    302
           X+     37         50       59      55        57    258
           Onc+   19^A^      28^P^    31^F^   29^B,L^   18    125
  ASC-US   Onc+   2          6^C,N^   4       2         4     18
  ASC-H    Onc+   2                   1 O                     3
  L-SIL    Onc+   2^M^                        2^D^      1     5
  H-SIL    Onc+   2^E^                                        2
  Total           116        137      156     161       143   713

^A-F,L-P^ CIN 2+ biopsy confirmed, ONC+RE = HR HPV targeted rescreening.

HPV typing and viral load cut-off for the visual detection of abnormal cytology/detection of CIN2+
--------------------------------------------------------------------------------------------------

HPV typing revealed 31 slides positive for oncogenic HPV types in the NFR group (6.1%), 50 in the MS group (10.0%) and 153 in the GS group (21.5%) (χ^2^= 73.1, *P* \< 0.001). There was no difference in viral load between the different HR HPV types (*P* \> 0.05). Therefore all HR HPV positives were pooled in the following analysis. Because all HPV HR positive slides (*n*= 234) were rescreened with knowledge of HPV type but without knowledge of viral load (blinded), we could calculate the viral load cut-off for the visual detection abnormal cytology (ASC-US+). The viral load of oncogenic positive slides, which were labelled ASC-US or higher (150.2 copies/cell), was significantly higher than the oncogenic positive slides, which were deemed negative after rescreening (25.9 copies/cell) (ANOVA; F-ratio = 8.894; *P*= 0.003). Receiver operating characteristic (ROC) curve analysis revealed a cut-off for ASC-US+ at 6.4508 copies/cell with a sensitivity of 54.4 and specificity of 82.4 with an area under the ROC curve of 0.698 and a 95%CI between 0.635--0.757 (Fig. [2](#fig02){ref-type="fig"} dotted line). For the detection of CIN2+ by HR HPV testing ROC curve analysis revealed a cut at 0.0142 copies/cell with a sensitivity of 100% and specificity of 88.3% with an area under the ROC curve of 0.956 and a 95%CI between 0.945 and 0.965 (Fig. [2](#fig02){ref-type="fig"} full line).

![ROC curve analysis for detection of CIN 2+ by cytology (ASC-US+ cases, dotted line) and by HR HPV viral load detection (full line).](jcmm0013-4051-f2){#fig02}

Discussion
==========

One of the advantages of using liquid cytology for the collection of cervical specimens is that multiple diagnostic tests can be performed on a single sample avoiding recall of women for additional testing. Additionally, the technique can easily be automated and combined with HPV testing on a large number of samples. In the present study, 1717 samples were analyzed, in all samples β-globin DNA could be amplified after proteine K digestion. Therefore the SurePath fixative provides an excellent preservation fluid allowing a simple DNA extraction.

Real-time PCR has the advantage of being highly specific for HR HPV detection, reproducible and capable of detecting viral load up to eight orders of magnitude in a linear range \[[@b23], [@b24]\]. In this study, 16 type-specific real-time PCRs were used to detect oncogenic HPV \[[@b22], [@b23]\]. Using the same real-time PCRs, Moberg and coworkers showed that the risk of developing cervical CIS or CIN 3 increases with higher viral load for most of the HPV types studied \[[@b25]\] and that HPV load is a type-dependent risk marker for invasive carcinoma \[[@b26]\]. Several studies have proven the prognostic value of HPV viral load in the evolution to cervical intraepithelial neoplasia \[[@b27]--[@b29]\].

Moreover, HPV viral load detection and typing by real-time PCR in cases of negative cytology has the possibility to calculate odd ratios for developing cancer for each individual slide.

In the present paper, HR HPV detection in cytologically negative samples was used in a QC setting. Our results show that the probability of detecting abnormal cell(s) in an LBC preparation is a function of the associated HPV viral load and that HR HPV detection has a higher sensitivity to detect CIN2+ than cytological rescreening. These results are concordant with the work of Schlecht *et al.*\[[@b30]\] and Bargas and de Marval \[[@b31]\]. Because HPV is an intracellular virus, the viral load is proportional to the number of infected cells. Therefore, the higher the viral load, the greater the number of infected cells on the slide and the greater the probability for the LBC test to be abnormal. Rescreening slides classified as NFR without knowledge of HR HPV status, revealed to be very insensitive. None of the CIN2+ cases were detected by full rescreening in this group. Only after HR targeted reviewing one of the three CIN 2+ cases could be detected. A possible explanation could be that the majority of NFR slides do not contain abnormal cells, and that only a limited number of NFR slides contain very few abnormal cells that can be detected more easily with knowledge of HR HPV positivity. Also, CIN2+ cases in the NFR group that were missed by full- or HR HPV-targeted rescreening had a high viral load, suggesting that no abnormal cells were present in these slides.

Considering that only 1.15% of negative cytology slides after GS in 2004 were included in this study, and that 11 CIN2+ cases were detected in negative cytology, a substantial number of CIN 2+ cases could have been missed by screening in 2004. None of the missed CIN 2+ cases by screening were HPV negative. The CIN 2+ cases missed by HR HPV-targeted rescreening were the cases with the lowest viral load. The viral load of five out of nine of these CIN 2+ cases was below the 6.4 copies/cell threshold. BD FocalPoint™ has categorized all confirmed CIN 2+ cases in the review group, with 50% of cases in the first two quintiles. Despite knowledge of quintile rank and HPV status, in 5 out of 11 of reviewed negative cytological preparations associated with histological CIN2+ the cytotechnicians/pathologists could not detect morphologically abnormal cells. Since three CIN2+ cases were categorized to the 4^th^ quintile, quintile ranking is not a useful criterion for increasing efficiency of full rescreening. A recent Swiss study showed that the probability for a PAP test to be abnormal is directly proportional to HPV viral load \[[@b31]\], and they suggested a theoretical limit for cytology sensitivity. Because rescreening of HPV ONC+ slides was blinded from the viral load results, the visual limit for the detection of cytological abnormal cells (ASC-US+) could be calculated. The most sensitive method for the detection of CIN2+ cases in normal cytology was oncogenic HPV detection by quantitative real-time PCR (100%). This was also a very specific method (87.2%). The specificity could further be increased to 88.3% by setting the viral load cut-off above 0.0142 HR HPV copies/cell. Only full rescreening was more specific, but only 23.5% of CIN2+ cases could be detected.

We therefore propose a new QC method for normal cytology: starting with the detection of oncogenic HPV by real-time PCR, which is both very sensitive and specific. HPV HR positive, cytologically negative cases should be rescreened or should be retested after 6 to 12 months. Cases with persistent HPV infection should be referred for further investigation. An additional advantage of this new QC method would be the elimination of false positive cytology since HPV negative cases would not be rescreened. Additionally, for slides positive for oncogenic HPV types with a viral load below the 6.5 copies/cell cut-off retesting the viral load after 6--12 months could determine if the HPV infection is transient or persistent and colposcopy is warranted. Women with a persistent HPV infection could be directed to colposcopy. Another advantage is the knowledge of the exact type of oncogenic HPV present. HPV 16 and 18 positive samples have a greater risk of developing cancer compared to intermediate oncogenic HPV types such as HPV 53, 66 and 67 \[[@b32]\].

The use of HR HPV detection as QC method instead of full rescreening would result in a 4.25 fold increase in CIN 2+ detection compared to full rescreening (17 instead of 4). The percentage of sample required for QC by HR HPV testing could be lowered to 2.5% compared to 10% in full rescreening as stated by guidelines, with a better result.
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